<DOC>
	<DOCNO>NCT00014677</DOCNO>
	<brief_summary>RATIONALE : NBI-3001 may able locate cancer cell stop grow . This may effective treatment glioblastoma multiforme . PURPOSE : Randomized phase II trial compare different regimens NBI-3001 follow surgery remove tumor treat patient glioblastoma multiforme .</brief_summary>
	<brief_title>NBI-3001 Followed Surgery Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety , tolerability , optimal clinical dose interleukin-4 ( 38-37 ) -PE38KDEL cytotoxin ( NBI-3001 ) follow surgical resection patient recurrent glioblastoma multiforme . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive interleukin-4 ( 38-37 ) -PE38KDEL cytotoxin ( NBI-3001 ) intratumorally continuous infusion 4-5 day begin within 12-36 hour ventricular catheter placement . Patients undergo surgical tumor resection approximately 3 week drug infusion . Cohorts 6 patient receive escalate dos NBI-3001 maximum tolerate dose determine . Patients follow within 1 week 8 , 16 , 26 week . PROJECTED ACCRUAL : Approximately 30-36 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Interleukin-4</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent progressive glioblastoma multiforme Previously treat cytoreductive surgery Unilateral , unifocal tumor volume 580 mL Not eligible radiotherapy due prior external beam radiotherapy No multifocal , brain stem , infratentorial tumor tumor invade midline No tumor clinically significant mass effect ( great 5 mm midline shift ) stable dose corticosteroid No clinical symptom attribute uncontrolled increase intracranial pressure and/or edema brain PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No focal generalize seizure ( ) within 30 day prior enrollment No prior concurrent malignancy except carcinoma situ cervix basal cell squamous cell skin cancer No medical instability due nonmalignant systemic disease No prior concurrent condition would preclude study compliance Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior antineoplastic chemotherapy Endocrine therapy : See Disease Characteristics Stable dose dexamethasone least 72 hour prior catheter placement Radiotherapy : See Disease Characteristics No prior radiosurgery boost ( e.g. , gamma knife stereotactic radiosurgery ) At least 8 week since prior radiotherapy Surgery : See Disease Characteristics At least 4 week since prior craniotomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>